Skip to main content
. 2024 Apr 16;42(8):909–917. doi: 10.1007/s11604-024-01566-8

Table 2.

Non-hematologic adverse effects

Grade 2 Grade 3 Grade 4–5
Acute phase 6 (29%) 1 (5%) 0
 Dermatitis 3 0 0
 Diarrhea 3 1 0
Late phase 5 (24%) 1 (5%) 0
 Proctitis 2 0 0
 Urinary tract obstruction 0 1 0
 Fracture 3 0 0